ArticleClinical nuclear medicine2026
Synchronous Late-Onset of Limbic Encephalitis and Tumefactive Demyelinating Lesion After the End of Immunotherapy.
Article in Clinical nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoreactive encephalitis is a very rare side effect of immunotherapy, which can lead to severe morbidity. Following azetolizumab, it typically occurs within 0-12 months, with a median of 15 days. In this case, immunoreactive encephalitis occurred 3.5 months after treatment with azetolizumab ended and 15.5 months after it began. Tumefactive demyelinating lesions represent a focal cerebral lesion with inflammatory demyelination. They are usually associated with multiple sclerosis, but can also occur drug-induced or in the context of autoantibody-mediated diseases. In MRI, tumefactive demyelinating lesions mimic cerebral metastases. 18 F-FDG PET/CT can enhance the diagnostic precision of both immunoreactive encephalitis and tumefactive demyelinating lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.